Cerebral proteome adaptations to amyloid angiopathy are prevented by carbonic anhydrase inhibitors
Alzheimer's & Dementia · 2025
DOI: 10.1002/alz.70122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Jasper Carlsen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Unit for Molecular Medicine (MMF), Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark. Hauptthemen laut MEDLINE: Proteome, Carbonic Anhydrase Inhibitors, Cerebral Amyloid Angiopathy, Acetazolamide. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Lundbeck Foundation, Alzheimer's Association, NIA NIH HHS.
Abstract (Originalsprache)
BACKGROUND Cerebral amyloid angiopathy (CAA) is a hallmark of Alzheimer's disease (AD), linked to adverse effects of emerging AD treatments. We explored the molecular effects of CAA in mouse brain and evaluated how these could be prevented by two repurposed United States Food and Drug Administration (FDA) approved treatments. METHODS Brain proteomics was performed on the Tg‐SwDI genetic mouse model carrying disease causing mutations and developing AD characteristic cognitive deficits and severe CAA. Cortical and hippocampal tissues from presymptomatic male and female mice were studied. RESULTS We identify a core of dysregulated proteins across studies, including established markers of AD as well as proteins indicative of astrogliosis and negative regulators of synaptic stability and function. Two FDA approved, repurposed carbonic anhydrase inhibitors (CAIs), acetazolamide and methazolamide, were effective in preventing these molecular adaptations. DISCUSSION The two drugs broadly prevent proteome adaptations to the detrimental genotype and retain glutamatergic synapse proteins significantly closer to wild‐type levels. Highlights The brain proteome changes of mice with CAA are mapped. Cortical and hippocampal tissues from presymptomatic male and female mice are studied. Markers of AD, astrogliosis, and synaptic stability are dysregulated. Two CAI are effective in preventing these protein changes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Unit for Molecular Medicine (MMF), Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark.
- Alzheimer's Center at Temple (ACT) and Department of Neural Sciences, Temple University, Philadelphia, Pennsylvania, USA.
- Center of Functionally Integrative Neuroscience (CFIN), Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark.
ORCID-Profile: Jasper Carlsen, Silvia Fossati, Leif Østergaard, Eugenio Gutiérrez-Jiménez
Förderung
- Lundbeck Foundation
- Alzheimer's Association
- NIA NIH HHS
- NINDS NIH HHS
- VELUX Foundation
Zitieren
APA
Carlsen, J., Fossati, S., Østergaard, L., Gutiérrez-Jiménez, E., & Palmfeldt, J. (2025). Cerebral proteome adaptations to amyloid angiopathy are prevented by carbonic anhydrase inhibitors. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70122
Vancouver
Carlsen J, Fossati S, Østergaard L, Gutiérrez-Jiménez E, Palmfeldt J. Cerebral proteome adaptations to amyloid angiopathy are prevented by carbonic anhydrase inhibitors. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70122
BibTeX
@article{Carlsen2025,
author = {Carlsen, Jasper and Fossati, Silvia and Østergaard, Leif and Gutiérrez-Jiménez, Eugenio and Palmfeldt, Johan},
title = {Cerebral proteome adaptations to amyloid angiopathy are prevented by carbonic anhydrase inhibitors},
journal = {Alzheimer's & Dementia},
year = {2025},
doi = {10.1002/alz.70122}
}
EUVIMED